These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 25895847

  • 1. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome.
    Efthymiou M, Lawrie AS, Mackie I, Arachchillage D, Lane PJ, Machin S, Cohen H.
    Thromb Res; 2015 Jun; 135(6):1191-7. PubMed ID: 25895847
    [Abstract] [Full Text] [Related]

  • 2. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N, RAPS Trial Protocol Collaborators.
    Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
    [Abstract] [Full Text] [Related]

  • 3. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant.
    Crowl A, Schullo-Feulner A, Moon JY.
    Ann Pharmacother; 2014 Nov; 48(11):1479-83. PubMed ID: 25104566
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.
    Cohen H, Efthymiou M, Devreese KMJ.
    J Thromb Haemost; 2021 Apr; 19(4):892-908. PubMed ID: 33325604
    [Abstract] [Full Text] [Related]

  • 8. Use of direct oral anticoagulants in antiphospholipid syndrome.
    Cohen H, Efthymiou M, Isenberg DA.
    J Thromb Haemost; 2018 Jun; 16(6):1028-1039. PubMed ID: 29624847
    [Abstract] [Full Text] [Related]

  • 9. Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination.
    Bijsterveld NR, Middeldorp S, Berends F, Büller HR.
    J Thromb Thrombolysis; 2000 Apr; 9(3):263-9. PubMed ID: 10728026
    [Abstract] [Full Text] [Related]

  • 10. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
    Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H.
    Thromb Res; 2015 Feb; 135(2):388-93. PubMed ID: 25555316
    [Abstract] [Full Text] [Related]

  • 11. Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time.
    Nilsson CU, Strandberg K, Reinstrup P.
    Scand J Clin Lab Invest; 2018 Sep; 78(5):358-364. PubMed ID: 29792060
    [Abstract] [Full Text] [Related]

  • 12. Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome.
    Isert M, Miesbach W, Schüttfort G, Weil Y, Tirneci V, Kasper A, Weber A, Lindhoff-Last E, Herrmann E, Linnemann B.
    Ann Hematol; 2015 Aug; 94(8):1291-9. PubMed ID: 25859986
    [Abstract] [Full Text] [Related]

  • 13. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome.
    Lawrie AS, Purdy G, Mackie IJ, Machin SJ.
    Br J Haematol; 1997 Sep; 98(4):887-92. PubMed ID: 9326184
    [Abstract] [Full Text] [Related]

  • 14. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.
    Perry SL, Samsa GP, Ortel TL.
    Thromb Haemost; 2005 Dec; 94(6):1196-202. PubMed ID: 16411394
    [Abstract] [Full Text] [Related]

  • 15. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
    Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H.
    J Thromb Haemost; 2014 Nov; 12(11):1801-9. PubMed ID: 25196808
    [Abstract] [Full Text] [Related]

  • 16. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
    Della Valle P, Crippa L, Garlando AM, Pattarini E, Safa O, Viganò D'Angelo S, D'Angelo A.
    Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
    [Abstract] [Full Text] [Related]

  • 17. Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing.
    Baumann Kreuziger LM, Datta YH, Johnson AD, Zantek ND, Shanley R, Reding MT.
    Blood Coagul Fibrinolysis; 2014 Apr; 25(3):232-6. PubMed ID: 24681704
    [Abstract] [Full Text] [Related]

  • 18. CoaguChek® XS versus standard laboratory prothrombin time for anticoagulant monitoring in patients with antiphospholipid syndrome.
    Fonseca MES, Balbi GGM, Signorelli F, Gouvea CP, de Andrade DCO.
    Lupus; 2022 Apr; 31(5):565-574. PubMed ID: 35266798
    [Abstract] [Full Text] [Related]

  • 19. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins.
    Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM.
    Br J Haematol; 2001 Dec; 115(3):672-8. PubMed ID: 11736953
    [Abstract] [Full Text] [Related]

  • 20. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
    Balaban M, Stanrić V, Rincić G, Ledinsky M, Grbac L, Stancić N, Tomasić H.
    Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.